bluebird bio (NASDAQ:BLUE) Lifted to “Buy” at Stifel Nicolaus

bluebird bio (NASDAQ:BLUE) was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research note issued on Thursday, The Fly reports.

Other research analysts have also issued reports about the company. Morgan Stanley decreased their target price on bluebird bio from $100.00 to $92.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Evercore ISI upgraded bluebird bio from an “in-line” rating to an “outperform” rating and raised their price target for the company from $86.00 to $100.00 in a research note on Monday, February 3rd. BidaskClub upgraded bluebird bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 21st. Zacks Investment Research cut bluebird bio from a “buy” rating to a “hold” rating and set a $87.00 price target on the stock. in a research note on Friday, February 21st. Finally, Wells Fargo & Co restated a “buy” rating on shares of bluebird bio in a research note on Thursday. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. bluebird bio currently has a consensus rating of “Buy” and an average target price of $124.94.

NASDAQ:BLUE traded down $0.75 during midday trading on Thursday, reaching $46.57. The company had a trading volume of 1,184,825 shares, compared to its average volume of 972,912. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -3.25 and a beta of 2.36. The stock’s fifty day simple moving average is $70.24 and its 200-day simple moving average is $83.66. bluebird bio has a 12-month low of $38.95 and a 12-month high of $163.43. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.13.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Tuesday, February 18th. The biotechnology company reported ($4.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.79) by ($0.25). The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $8.23 million. bluebird bio had a negative net margin of 1,767.49% and a negative return on equity of 51.23%. The company’s revenue for the quarter was down 47.9% on a year-over-year basis. During the same quarter last year, the business posted ($2.72) earnings per share. As a group, sell-side analysts expect that bluebird bio will post -15.64 EPS for the current year.

In other news, CFO William D. Baird III sold 1,254 shares of bluebird bio stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $90.60, for a total transaction of $113,612.40. Following the sale, the chief financial officer now owns 13,746 shares in the company, valued at $1,245,387.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Philip D. Gregory sold 600 shares of bluebird bio stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $94.03, for a total value of $56,418.00. Following the sale, the insider now owns 25,308 shares in the company, valued at approximately $2,379,711.24. The disclosure for this sale can be found here. Insiders have sold 12,784 shares of company stock worth $1,149,985 in the last quarter. Insiders own 3.00% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of BLUE. State Street Corp raised its holdings in bluebird bio by 11.1% in the 3rd quarter. State Street Corp now owns 1,304,238 shares of the biotechnology company’s stock valued at $119,755,000 after acquiring an additional 130,765 shares during the last quarter. Peregrine Capital Management LLC increased its holdings in bluebird bio by 13.3% in the 4th quarter. Peregrine Capital Management LLC now owns 132,367 shares of the biotechnology company’s stock valued at $11,615,000 after purchasing an additional 15,562 shares in the last quarter. First Trust Advisors LP increased its holdings in bluebird bio by 29.1% in the 4th quarter. First Trust Advisors LP now owns 566,412 shares of the biotechnology company’s stock valued at $49,703,000 after purchasing an additional 127,834 shares in the last quarter. Usca Ria LLC increased its holdings in bluebird bio by 48.0% in the 4th quarter. Usca Ria LLC now owns 19,932 shares of the biotechnology company’s stock valued at $1,749,000 after purchasing an additional 6,462 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in bluebird bio by 49.0% in the 4th quarter. Bank of Montreal Can now owns 14,362 shares of the biotechnology company’s stock valued at $1,260,000 after purchasing an additional 4,720 shares in the last quarter.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Read More: What are the benefits of investing in REITs?

The Fly

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.